On Nov. 20, 2012, the FDA approved a seasonal flu vaccine produced by Novartis using animal cell culture rather than the traditional manufacturing using chicken eggs – a speedier process that could help build stockpiles in the event of a pandemic. The vaccine was sold by the Swiss drugmaker under the brand name Flucelvax, and was approved to prevent season influenza in people aged 18 and over.